Cardiogenesis Corporation to Present at OneMedForum 2010 Emerging Company Finance Forum

Wednesday, January 6, 2010 Press Release J E 4

IRVINE, Calif., Jan. 6 Cardiogenesis Corporation (Pink Sheets: CGCP) today announced that it is scheduled to present at the 2010 OneMedPlace Finance Forum to be held at the Sir Francis Drake Hotel in San Francisco. Executive Chairman, Paul J. McCormick will present a 30-minute corporate overview next Tuesday, January 12, 2010 at 3:00 pm Pacific time (6:00 pm Eastern time) and meet one-on-one with investors during the conference.

The annual OneMedForum provides an opportunity for the most promising emerging healthcare and life science companies to present to and interact with a diverse group of global investors and partners. The forum is held at the Sir Francis Drake Hotel in San Francisco, during the Healthcare community's largest gathering of the year - the JP Morgan Healthcare Conference.

Throughout the two days, over 100 CEOs will present their company to 500+ OneMedForum guests. In attendance will be institutional investors, venture capitalists, private investors, business development executives, and industry executives from across the healthcare landscape.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. For more information on the company and its products, please visit the Cardiogenesis company website at or the direct to patient website at

SOURCE Cardiogenesis Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New Product Proven to Enhance the Healing of Dry F...
MAP Pharmaceuticals to Present at the 28th Annual ...